{
    "clinical_study": {
        "@rank": "42081", 
        "brief_summary": {
            "textblock": "To make intravenous (IV) ganciclovir available to immunocompromised patients with\n      life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of\n      the disease are too severe to allow admission to a controlled clinical study of ganciclovir\n      therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of\n      ganciclovir IV followed by a maintenance course of ganciclovir IV for an indefinite\n      duration. To tabulate the patient's clinical response."
        }, 
        "brief_title": "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient", 
        "condition": [
            "Cytomegalovirus Infections", 
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cytomegalovirus Infections", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Cytomegalovirus (CMV) disease who meet the criteria for a treatment IND protocol, or\n             other clinical studies, including controlled clinical studies of anticytomegalovirus\n             therapy in peripheral CMV retinitis in patients with AIDS.\n\n          -  Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome\n             (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered\n             immediately life-threatening.\n\n          -  Transplant patients in whom trial reduction of immunosuppressive drug treatment is\n             feasible.\n\n          -  Children with congenital or neonatal CMV where there is not a documented primary or\n             acquired immunodeficiency.\n\n          -  Hypersensitivity to acyclovir or ganciclovir.\n\n          -  Receiving antimetabolite treatment that cannot be discontinued.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antimetabolites.\n\n          -  Alkylating agents.\n\n          -  Nucleoside analogs (topical ophthalmics are permitted).\n\n          -  Interferon.\n\n          -  Foscarnet.\n\n          -  Cytokines.\n\n        Patients with the following are excluded:\n\n          -  Cytomegalovirus (CMV) infection who meet the criteria for a treatment IND protocol,\n             or other clinical studies, including controlled clinical studies of\n             anticytomegalovirus therapy in peripheral CMV retinitis in patients with AIDS.\n\n          -  Mild to moderate CMV infections who fail to meet the severity criteria. CMV syndrome\n             (i.e., cytopenia, increased liver enzymes, fever, viremia, viruria) is not considered\n             immediately life-threatening.\n\n          -  Transplant patients in whom trial reduction of immunosuppressive drug treatment is\n             feasible.\n\n          -  Children with congenital or neonatal CMV where there is not a documented primary or\n             acquired immunodeficiency.\n\n          -  Hypersensitivity to acyclovir or ganciclovir.\n\n          -  Receiving antimetabolite treatment that cannot be discontinued.\n\n        Patients must qualify as follows:\n\n          -  Previously enrolled in compassionate use study (ICM 1257/1257A) or have terminated\n             from another Syntex ganciclovir study.\n\n          -  Diagnosis of AIDS and life-threatening Cytomegalovirus (CMV) infection.\n\n          -  Diagnosis of other immunodeficiencies other than AIDS, with life-threatening or\n             sight-threatening CMV disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Months"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002025", 
            "org_study_id": "029D", 
            "secondary_id": "ICM 1691"
        }, 
        "intervention": {
            "intervention_name": "Ganciclovir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ganciclovir"
        }, 
        "keyword": [
            "Retinitis", 
            "AIDS-Related Opportunistic Infections", 
            "Immune Tolerance", 
            "Injections, Intravenous", 
            "Ganciclovir", 
            "Cytomegalovirus Infections", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94303"
                }, 
                "name": "Roche Global Development - Palo Alto"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002025"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 1989"
    }, 
    "geocoordinates": {
        "Roche Global Development - Palo Alto": "37.442 -122.143"
    }
}